Tasly Pharmaceutical Group Co., Ltd. (600535) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Tasly Pharmaceutical Group Co., Ltd.

Why is Tasly Pharmaceutical Group Co., Ltd. ?

Poor long term growth as Net Sales has grown by an annual rate of -9.48% and Operating profit at -2.22% over the last 5 years

Negative results in Dec 25

OPERATING CASH FLOW(Y) Lowest at CNY 912.93 MM
NET PROFIT(Q) At CNY 112.86 MM has Fallen at -55.59%
DIVIDEND PAYOUT RATIO(Y) Lowest at 0%

Below par performance in long term as well as near term

Along with generating -5.94% returns in the last 1 year, the stock has also underperformed China Shanghai Composite in the last 3 years, 1 year and 3 months

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Tasly Pharmaceutical Group Co., Ltd. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Tasly Pharmaceutical Group Co., Ltd. for you?

Low Risk, Low Return

Absolute

Risk Adjusted

Volatility

Tasly Pharmaceutical Group Co., Ltd.

-2.67%

0.15

18.40%

China Shanghai Composite

24.7%

1.58

14.20%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-9.48%

EBIT Growth (5y)

-2.22%

EBIT to Interest (avg)

15.07

Debt to EBITDA (avg)

Net Debt is too low

Net Debt to Equity (avg)

-0.09

Sales to Capital Employed (avg)

0.59

Tax Ratio

16.92%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

0.02%

ROCE (avg)

9.92%

ROE (avg)

10.17%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

1.90

EV to EBIT

19.44

EV to EBITDA

13.50

EV to Capital Employed

2.12

EV to Sales

2.53

PEG Ratio

Dividend Yield

3.39%

ROCE (Latest)

10.91%

ROE (Latest)

7.88%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Mildly Bearish

RSI

No Signal

Bollinger Bands

Mildly Bullish

Sideways

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Mildly Bearish

Dow Theory

Mildly Bullish

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

4What is working for the Company

ROCE(HY)

Highest at 9.03%

INTEREST COVERAGE RATIO(Q)

The company hardly has any interest cost

-15What is not working for the Company

OPERATING CASH FLOW(Y)

Lowest at CNY 912.93 MM

NET PROFIT(Q)

At CNY 112.86 MM has Fallen at -55.59%

DIVIDEND PAYOUT RATIO(Y)

Lowest at 0%

RAW MATERIAL COST(Y)

Grown by 101.54% (YoY

CASH AND EQV(HY)

Lowest at CNY 3,488.96 MM

DEBT-EQUITY RATIO (HY)

Highest at 0 %

INVENTORY TURNOVER RATIO(HY)

Lowest at 0 times

DEBTORS TURNOVER RATIO(HY)

Lowest at 0 times

DIVIDEND PER SHARE(HY)

Lowest at CNY 0

NET SALES(Q)

Lowest at CNY 1,925.8 MM

PRE-TAX PROFIT(Q)

At CNY 187.91 MM has Fallen at -38.83%

EPS(Q)

Lowest at CNY 0

Here's what is not working for Tasly Pharmaceutical Group Co., Ltd.

Operating Cash Flow

Lowest at CNY 912.93 MM and Fallen

In each year in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (CNY MM)

Net Profit

At CNY 112.86 MM has Fallen at -55.59%

over average net sales of the previous four periods of CNY 254.1 MM

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (CNY MM)

Net Sales

Lowest at CNY 1,925.8 MM

in the last five periods

MOJO Watch

Near term sales trend is negative

Net Sales (CNY MM)

Pre-Tax Profit

At CNY 187.91 MM has Fallen at -38.83%

over average net sales of the previous four periods of CNY 307.21 MM

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (CNY MM)

EPS

Lowest at CNY 0

in the last five periods

MOJO Watch

Declining profitability; company has created lower earnings for shareholders

EPS (CNY)

Cash and Eqv

Lowest at CNY 3,488.96 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents

Debt-Equity Ratio

Highest at 0 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Inventory Turnover Ratio

Lowest at 0 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling inventory has slowed

Inventory Turnover Ratio

Debtors Turnover Ratio

Lowest at 0 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio

Dividend per share

Lowest at CNY 0

in the last five years

MOJO Watch

Company is distributing lower dividend than previous years

DPS (CNY)

Dividend Payout Ratio

Lowest at 0%

in the last five years

MOJO Watch

Company is distributing lower proportion of profits generated as dividend

DPR (%)

Raw Material Cost

Grown by 101.54% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales